Endoskopie 2008; 17(3): 59-63

Quality of transurethral resection in immediate and high risk primary non-muscle invasive bladder cancer

MUDr. Roman Tomaškin
Urologická klinika JLF UK, Martin

The aim of study was to evaluate the quality of primary transurethral resection of bladder tumour, to determine the incidence of residual

tumour (RT) and the impact of clinical and histopathological characteristics of primary tumour on the risk of occurence of RT. Consecutive

260 patients with intermediate and high risk primary non-muscle invasive bladder cancer were included in the study, repeat TUR

was performed in 124 patients. Gender, age, pT stage, grade, number and diameter of primary tumours, presence/absence of muscle in

TUR specimen and intravesical instillation of epirubicin within 6 hours after TUR were evaluated. Statistical univariate and multivariate

analysis was performed. In our cohort the incidence of RT was 40 % with 2.4 % incidence of muscle invasion revealed in reTUR specimen.

Significant predictors of RT were grade and unfavourable cystoscopic findings. Immediate intravesical epirubicin instillation did not

change the incidence of RT. The absence of muscle in primary TUR specimen did not lead to the increased incidence of RT.

Keywords: bladder neoplasms, transurethral resection, reTUR, residual tumour.

Published: March 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tomaškin R. Quality of transurethral resection in immediate and high risk primary non-muscle invasive bladder cancer. Endoskopie. 2008;17(3):59-63.
Download citation

References

  1. Kirkali Z, Chan T, Manoharan M, et al. Bladder Cancer: Epidemiology, staging and grading, and diagnosis. Urology, 2005; 66(Suppl 6A): 4-34. Go to original source... Go to PubMed...
  2. Brausi M, Collette L, Kurth K. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A Combined analysis of seven EORTC studies. Eur Urol, 2002; 41: 523-531. Go to original source... Go to PubMed...
  3. Grimm MO, Steinhoff Ch, Simon X. Effect of routine repeat transurethral resection for superficial bladder cancer: A long-term observational study. J Urol, 2003; 170: 433-437. Go to original source... Go to PubMed...
  4. Schwaibold HE, Sivalingam S, May F, et al. The value of a second transurethral resection for T1 bladder cancer, BJU Int, 2006; 97: 1199-1201. Go to original source... Go to PubMed...
  5. Horňák M, Galbavý Š, Bárdoš A. Histopatologická charakteristika nádorov močového mechúra: Analýza vlastného materiálu podľa WHO klasifikácie 2004. Klin urol, 2006; 2: 66-69.
  6. Miladi M, Pyeromaure M, Zerbib M, et al. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol, 2003; 43: 241-245. Go to original source... Go to PubMed...
  7. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol, 1999; 162: 74-76. Go to original source... Go to PubMed...
  8. Herr HW, Donat SM. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int, 2006; 97: 1194-1198. Go to original source... Go to PubMed...
  9. Herr HW, Donat SM, Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol, 2007; 177: 75-79. Go to original source... Go to PubMed...
  10. Divrik RT, Yildirim Ü, Zorlu F, et al. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: A prospective, randomized clinical trial. J Urol, 2006; 175: 1641-1644. Go to original source... Go to PubMed...
  11. Cheng L, Neumann RM, Weaver AL, et al. Grading and staging of bladder carcinoma in transurethral resection specimens. Am J Clin Pathol, 2000; 113: 275-279. Go to original source... Go to PubMed...
  12. Wijkström H, Norming U, Lagerkvist M, et al. Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term followup of 276 consecutive patients. Br J Urol, 1998; 81: 686-691. Go to original source... Go to PubMed...
  13. Bernardini S, Billerey C, Martin M, et al. The predictive value of muscularis mucosae invasion and p53 overexpression on progression of stage T1 bladder carcinoma. J Urol, 2001; 165: 42-46. Go to original source... Go to PubMed...
  14. Herr HW. Does cystoscopy correlate with histology of recurrent papillary tumours of the bladder? BJU Int, 2001; 88: 683-685. Go to original source... Go to PubMed...
  15. Carmack AJK, Soloway, MS. The diagnosis and staging of bladder cancer: From RBCs to TURs. Urology, 2006; 67(Suppl 3A): 3-10. Go to original source... Go to PubMed...
  16. Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: Is cystectomy often too early? J Urol, 2001; 165: 808-810. Go to original source... Go to PubMed...
  17. Klän R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol, 1991; 146: 316-318. Go to original source... Go to PubMed...
  18. Köhrmann KU, Woeste M, Kappers JH, et al. Der wert der transurethralen nachresektion beim oberflächlichen Harnblasenkarzinom. Akt Urol, 1994; 25: 208-213. Go to original source...
  19. Schips L, Augustin H, Zigeuner RE, et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology, 2002; 59: 220-223. Go to original source... Go to PubMed...
  20. Rigaud J, Karam G, Braud G, et al. Value of second endoscopic resection in stage T1 bladder tumors. Prog Urol, 2002; 12: 27-30. Go to PubMed...
  21. Mersdorf A, Brauers A, Wolff JM, et al. Second transurethral resection for superficial bladder cancer: a must? J Urol, 1998; 159(Suppl): 143, A542. Go to PubMed...
  22. Lodde M, Lusuardi L, Palermo S, et al. En bloc transurethral resection of bladder tumors: Use and limits. Urology, 2003; 62: 1089-1091. Go to original source... Go to PubMed...




Endoscopy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.